In an interview with an Italian newspaper, published on Sunday, a senior official in the European Medicines Agency advised to abandon vaccination with the AstraZeneca vaccine if other vaccines are available. He preferred to vaccinate people over the age of 60 with the Johnson & Johnson vaccine, because it causes "fewer problems". But the European Medicines Agency, in a comment on the official's statement, considered that "the benefits of the vaccine outweigh its risks." The agency had licensed the vaccine, but cases of blood clots were recorded in some of its recipients. </p><div> <p>In an interview with the Italian newspaper "La Stampa" published on Sunday, a senior official of the European Medicines Agency advised to stop vaccination <strong><a target="_blank" href="https://www.france24.com/ar/أوروبا/20210527-فيروس-كورونا-علماء-ألمان-يتوصلون-لأسباب-حدوث-تجلط-الدم-لدى-بعض-من-تلقوا-اللقاحات" rel="noopener">AstraZeneca Vaccine</a></strong> Anti-Covid-19 for all age groups when other vaccines are available.
The official in charge of the vaccine strategy at the agency, Marco Cavalieri, indicated to the newspaper that he prefers using the Johnson & Johnson vaccine for those over the age of sixty.
Is it necessary to stop the vaccination AstraZeneca?
When asked if AstraZeneca should be discontinued, including for people over the age of 60, Cavalieri replied: “Yes, and it is an option that many countries, such as France and Germany, are considering, given the increased availability of messenger RNA vaccines.”
“However, accidents are very rare and occurred after the first dose. It is true that there is less data on the second dose, but (the vaccination program) in the UK is going well,” the official added.
Marco Cavalieri explained that the Johnson & Johnson vaccine, which is given in a single dose, poses “fewer problems than AstraZeneca”, but it is used on a smaller scale.
And he continued, “By restricting it to only one dose, it is good for some groups that are difficult to reach, but it (the vaccine) is based on a modified adenovirus, and it is better to limit its use to those over the age of sixty.”
‘The benefits of the vaccine outweigh the risks’
In a brief comment later posted on Twitter, the European Medicines Agency condemned the “disinformation (which) is currently prevalent”.
The agency stressed that “the situation is the following: the benefits of the AstraZeneca vaccine outweigh its risks, and it is licensed for all categories.”
The European Medicines Agency has licensed the two vaccines for people over the age of 18, but some people who received them have reported rare blood clots.
On Saturday, Italy decided to limit the administration of the AstraZeneca vaccine to people over the age of sixty, due to its high health risks to young people.
The difference between AstraZeneca and other vaccines اللقاح
The messenger RNA technology in most coronavirus vaccines relies on injecting genetic instructions into cells to prompt them to produce proteins or “antigens” specific to the coronavirus. These proteins are transferred to the immune system, which produces antibodies.
As for viral vector vaccines, such as AstraZeneca and Johnson & Johnson, they are based on another virus that is modified to provide the body with genetic information to combat Covid-19. Both vaccines use a common type of virus called adenovirus.